Drug Patent Watch
MARCH 22, 2022
FEATURED ARTICLE Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications…. The post DrugPatentWatch Week in Review appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
MARCH 24, 2022
The ranking was calculated on cost and time efficiencies and United States was shown to be the most efficient jurisdiction on speed of business whereas Brazil, South Korea and China scored less favorably
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
MARCH 21, 2022
Time for Drug Channels Institute’s annual update on the gross-to-net bubble —the ever-growing dollar gap between sales at brand-name drugs' list prices and their sales at net prices after rebates and other reductions. We estimate that the gross-to-net bubble reached $204 billion for patent-protected brand-name drugs in 2021. If we include brand-name drugs that have lost patent protection and face competition from generic equivalents, the bubble was even higher, at $236 billion.
The Pharma Data
MARCH 25, 2022
Maximizing potential of traditional medicines through modern science and technology. The World Health Organization (WHO) and the Government of India today signed an agreement to establish the WHO Global Centre for Traditional Medicine. This global knowledge centre for traditional medicine, supported by an investment of USD 250 million from the Government of India, aims to harness the potential of traditional medicine from across the world through modern science and technology to improve the heal
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Patent Watch
MARCH 22, 2022
Drugs contain ingredients with therapeutic activity, so-called “active ingredients” as well as inactive ingredients. These inactive ingredients, called excipients, are included in oral products for various reasons, such as to…. The post 2 Strategies to Grow Your Excipient Business by Tracking Drug Patents appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Channels
MARCH 25, 2022
Today’s guest post comes from Ian Ocilka, Senior VP of Client Solutions at ConnectiveRx. Ian explains some of the challenges associated with negotiating the medical benefit for both patients and providers. He goes on to describe the need for combining technology solutions and meaningful human connection for improved patient outcomes. To learn more, join experts from ConnectiveRx on April 26th at 1 pm ET for a free, online panel discussion: The Evolving Medical Benefits Landscape—Are you Ready fo
The Pharma Data
MARCH 23, 2022
Roche today announced the donation of additional medicines and diagnostics to Ukraine. Beyond the already communicated 150,000 packs of an antibiotic medicine the new donation includes another 4,600 packs of specialized medicines for the treatment of influenza, rheumatoid arthritis, SMA and various cancers. We are also donating reagents and consumables for automatic testing of up to 120,000 blood donations and 31,000 units for diabetes management.
Drug Patent Watch
MARCH 23, 2022
This chart shows the pharmaceutical companies with the most patents in Slovakia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.
EG Life Sciences
MARCH 21, 2022
Throughout the Biopharma industry, organizations are applying Agile principles and practices to get drugs to market faster and keep up with demands following the pandemic. Eliassen Group and EG Life Sciences have been working hand in hand with experts in many different fields – not just IT – to ensure that these organizations successfully achieve the benefits of enterprise agility.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug & Device Law
MARCH 25, 2022
When Merck Sharp & Dohme Corp. v. Albrecht , 139 S. Ct. 1668 (U.S. 2019), was decided, we included it as both our best decision of 2019 , and as our sixth worst case. To us, Albrecht ’s holding that all preemption issues are questions of law for the judge to decide overcame the uncertainties created by Court’s tinkering with the “clear evidence” preemption test.
The Pharma Data
MARCH 23, 2022
– ELEVATE 12 study met primary and key secondary endpoints of improving clinical remission at week 12 – – Safety profile consistent with previous Phase 2 studies – Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of moderately to severely active ulcerative colitis (UC).
Drug Patent Watch
MARCH 25, 2022
This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 25, 2022
Annual Drug Patent Expirations for FINTEPLA Fintepla is a drug marketed by Zogenix Inc and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Zogenix Inc drug FINTEPLA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
MARCH 25, 2022
Annual Drug Patent Expirations for QINLOCK Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are five patents protecting this drug. This drug has…. The post New patent for Deciphera Pharms drug QINLOCK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 25, 2022
Annual Drug Patent Expirations for RECORLEV Recorlev is a drug marketed by Strongbridge and is included in one NDA. There are five patents protecting this drug. This drug has twenty-seven…. The post New patent for Strongbridge drug RECORLEV appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 24, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Romania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Romania? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
MARCH 23, 2022
A special supplement from WHO and HRP , newly published in BMJ Global Health , spotlights how women and their newborn babies are treated during childbirth and offers a path to improved facility-based care. More and more evidence showsthat women across the world face unacceptable mistreatment during childbirth. Women everywhere face violations of their rights – including rights to privacy, informed consent, and the right have a trusted companion of choice throughout childbirth. .
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
The Pharma Data
MARCH 23, 2022
To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives. Now scientists at La Jolla Institute for Immunology (LJI) and Scripps Research have found a promising strategy for stopping Ebola virus polymerase.
Drug Patent Watch
MARCH 23, 2022
Annual Drug Patent Expirations for SPIRIVA Spiriva is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from two suppliers. There are sixteen patents…. The post New patent expiration for Boehringer Ingelheim drug SPIRIVA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 23, 2022
Annual Drug Patent Expirations for JARDIANCE Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from four suppliers. There are seven patents…. The post New patent for Boehringer Ingelheim drug JARDIANCE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 23, 2022
Annual Drug Patent Expirations for XELJANZ+XR Xeljanz Xr is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. There are four patents…. The post New patent for Pfizer drug XELJANZ XR appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
MARCH 23, 2022
Annual Drug Patent Expirations for GAVRETO Gavreto is a drug marketed by Genentech Inc and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent for Genentech Inc drug GAVRETO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 23, 2022
Annual Drug Patent Expirations for ROZLYTREK Rozlytrek is a drug marketed by Genentech Inc and is included in one NDA. It is available from one supplier. There are thirteen patents…. The post New patent for Genentech Inc drug ROZLYTREK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 22, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in France. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in France? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 22, 2022
Annual Drug Patent Expirations for COTELLIC Cotellic is a drug marketed by Genentech Inc and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Genentech Inc drug COTELLIC appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 22, 2022
Annual Drug Patent Expirations for VAZALORE Vazalore is a drug marketed by Plx Pharma and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent expiration for Plx Pharma drug VAZALORE appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
MARCH 22, 2022
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease. PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that data from its cardiovascular portfolio will be presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), taking place in Washington, DC, and virtually, fro
The Pharma Data
MARCH 22, 2022
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research Submissions for Ruminant Well-Being Awards and Gustav Rosenberger Memorial Fund grant open now. Boehringer Ingelheim, a global leader in animal health supports farmers and veterinarians worldwide in their work and promotes better farming practices to achieve long-term, positive impact not only in terms of animal health, but also in terms of well-being.
The Pharma Data
MARCH 22, 2022
Co-founded at Fred Hutchinson Cancer Research Center with Phil Greenberg, M.D., Aude Chapuis, M.D., and Tom Schmitt, Ph.D., and Vida Ventures along with serial entrepreneurs Arjun Goyal, M.D., M.Phil., and Jak Knowles, M.D./ Foundational cell therapy platform builds upon seminal work from co-founders, leveraging a T Cell Receptor (TCR) discovery engine and suite of synthetic biology components intending to develop potentially best-in-class therapies targeting oncogenic driver mutations like KRAS
Expert insights. Personalized for you.
120 
Let's personalize your content